Description: Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Home Page: www.santhera.com
Hohenrainstrasse 24
Pratteln,
4133
Switzerland
Phone:
41 61 906 89 50
Officers
| Name | Title |
|---|---|
| Dr. Thomas Meier Ph.D. | Founder & Chairman |
| Mr. Dario Eklund | Chief Exec. Officer |
| Mr. Andrew P. Smith CGMA, FCMA | Chief Financial Officer |
| Mr. Marc Schrader | Head of Technical Devel. & Operations |
| Ms. Eva Kalias | Head of Investor Relations & Communications |
| Mr. Oliver Strub | Exec. VP, Gen. Counsel & Sec. |
| Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management |
| Ms. Sarah Holmes-Klotz | Head of People & Culture |
| Mr. Günther Metz Ph.D. | Head of Bus. Devel. & Exec. VP |
| Mr. Shabir Hasham M.D. | Chief Medical Officer |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 30.5244 |
| Price-to-Sales TTM: | 276.1904 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |